Home » Janssen, Hanmi ink diabetes and obesity agreement
Janssen, Hanmi ink diabetes and obesity agreement
November 11, 2015
Janssen Pharmaceuticals has obtained worldwide rights, excluding China and Korea, to develop and commercialize oxyntomodulin-based therapies including HM12525A, a biologic that is completing phase I and expected to enter phase II studies next year, from Hanmi Pharmaceutical. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.
HM12525A is an oxyntomodulin-based therapy (GLP-1/glucagon receptor dual agonist) that has shown evidence of improving multiple metabolic parameters that lead to improved blood glucose, body weight, and insulin sensitivity. That asset has the potential, as a once weekly therapy, to be a best-in-class oxyntomodulin-based therapy.
Upcoming Events
-
21Oct